<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BB4F4A84-8E6D-4147-8AE7-8360714E4BEC"><gtr:id>BB4F4A84-8E6D-4147-8AE7-8360714E4BEC</gtr:id><gtr:name>Enzon Pharmaceuticals, Inc.</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:department>Medicine</gtr:department><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BB4F4A84-8E6D-4147-8AE7-8360714E4BEC"><gtr:id>BB4F4A84-8E6D-4147-8AE7-8360714E4BEC</gtr:id><gtr:name>Enzon Pharmaceuticals, Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9B09A6F0-D68C-46BF-B007-338220BBA422"><gtr:id>9B09A6F0-D68C-46BF-B007-338220BBA422</gtr:id><gtr:firstName>Stanley</gtr:firstName><gtr:surname>Kaye</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/75E0ACFC-D978-4C46-B192-027302ABC124"><gtr:id>75E0ACFC-D978-4C46-B192-027302ABC124</gtr:id><gtr:firstName>Florence</gtr:firstName><gtr:surname>Raynaud</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CA7229D6-679A-46E0-9480-1E4A741DA8F6"><gtr:id>CA7229D6-679A-46E0-9480-1E4A741DA8F6</gtr:id><gtr:firstName>Andy</gtr:firstName><gtr:surname>Norman</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1C96D9C8-2FE2-4C0F-A690-F20626A4759A"><gtr:id>1C96D9C8-2FE2-4C0F-A690-F20626A4759A</gtr:id><gtr:firstName>Gerhardt</gtr:firstName><gtr:surname>Attard</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E78313EF-B2FD-4FE8-987E-F0E13BA6CB24"><gtr:id>E78313EF-B2FD-4FE8-987E-F0E13BA6CB24</gtr:id><gtr:firstName>Colin Stephen</gtr:firstName><gtr:surname>Cooper</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7910ADC1-0186-440A-B7DF-E8F1807432B9"><gtr:id>7910ADC1-0186-440A-B7DF-E8F1807432B9</gtr:id><gtr:firstName>David Paul</gtr:firstName><gtr:surname>Dearnaley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C5EA052E-91B5-4408-ACD8-63E2FBE255D4"><gtr:id>C5EA052E-91B5-4408-ACD8-63E2FBE255D4</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Workman</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3A1B9180-9C4D-4FE8-B990-1ED04D7B21B6"><gtr:id>3A1B9180-9C4D-4FE8-B990-1ED04D7B21B6</gtr:id><gtr:firstName>Mitch</gtr:firstName><gtr:surname>Dowsett</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/20D66D84-A34B-4A54-A9D4-A29257DB15A7"><gtr:id>20D66D84-A34B-4A54-A9D4-A29257DB15A7</gtr:id><gtr:firstName>Jeremy</gtr:firstName><gtr:surname>Clark</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/942D2AA5-E744-4398-84D8-E1B53CDCDD55"><gtr:id>942D2AA5-E744-4398-84D8-E1B53CDCDD55</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Parker</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1D20065C-DD9B-4CA9-8597-56BB5EE78FE0"><gtr:id>1D20065C-DD9B-4CA9-8597-56BB5EE78FE0</gtr:id><gtr:firstName>Johann</gtr:firstName><gtr:otherNames>Sebastian</gtr:otherNames><gtr:surname>de Bono</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601308"><gtr:id>DF1B40A4-9EC6-4F91-89BE-49AD1D6444C7</gtr:id><gtr:title>Circulating Tumour Cell Enumeration and Molecular Evaluation in Patients with Advanced Prostate Carcinoma.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601308</gtr:grantReference><gtr:abstractText>Prostate cancer is the second commonest cause of death from cancer in men. Little progress has been made in the treatment of this disease since testicular testosterone deprivation was identified as a therapeutic modality. There is an urgent need to accelerate the development of novel therapies for this disease. Key bottlenecks to the treatment of this disease include poor clinical predictors of which drugs result in clinical benefit, and lack of access to hormone resistant cancer cells to understand the biology of the disease. This results in protracted trials, lasting many years, evaluating whether new treatments prolong time to death of large numbers of patients. It is envisioned that the enumeration, separation and study of prostate cancer cells in the blood of patients using validated new technology will expedite clinical trials and allow access to tumour cells for the study of the biology of this disease, leading to improvements in treatment for this unmet need.</gtr:abstractText><gtr:technicalSummary>Circulating tumour cells (CTC) can be reliably quantitated by the CellTracks? System (Immunicon, PA), which allows the automated detection and isolation of rare cancer cells from blood to GCLP. CTC are not detected in healthy subjects or in non-malignant diseases. In breast cancer, CTC counts predict outcome and response to therapy (FDA approved test). 

CTC are detected most frequently in prostate cancer patients. We have studied CTC in over 300 men with castration refractory prostate cancer (CRPC), with CTC being detected in 60-70% of men (Median 5 CTC/7.5 mls blood; Range: 0-6000 CTC). These studies indicate that in CRPC, CTC counts predict survival. We have successfully characterized CTC by immunofluorescence for protein expression and by FISH for DNA amplification and TMPRSS2/ETS gene translocations. 

These findings are of critical importance since in CRPC access to tumour tissue is not usually feasible. Moreover, most patients do not have measurable disease, with treatment decisions being based on PSA levels. Better predictors of clinical benefit such as CTC counts are urgently needed to improve outcome. Repeated access to CTC for molecular analysis also provides a powerful tool for identifying molecular markers of response and resistance.

Hypothesis
1. CTC count changes predict clinical benefit from treatment in patients with CRPC. 
2. CTCs can be molecularly characterised and can be utilized for biomarker studies in clinical trials of rationally designed, molecularly targeted drugs. 
3. Molecular changes induced by targeted drugs, or at disease progression, can be detected in CTC, and can impact anticancer drug development in CRPC patients. 

Proposal: We propose the study of CTC in patients with CRPC, focusing on forthcoming randomised studies of a small molecule inhibitor of androgen synthesis generated at this institution, and now outlicensed to Cougar Biotechnology. This small molecule, abiraterone, irreversibly inhibits CYP17 and in ongoing trials has minimal toxicity and impressive antitumour activity (over 50% PSA decline rate: 70%) in CRPC patients failing all known hormonal therapies including LHRH analogues, androgen antagonists, steroids, ketoconazole and diethystilboestrol.
Key aims:
1.To evaluate whether CTC counts can be utilized as surrogates of clinical benefit in therapeutic trials for CRPC patients. 
2. To evaluate the utility of the molecular characterization of CTCs in the treatment of CRPC patients with molecularly targeted drugs
3. To determine mechanisms of drug resistance by studying CTCs.


Implications: It is envisioned that this work will accelerate clinical drug development for advanced prostate cancer patients, leading to improved treatment of an unmet clinical need.</gtr:technicalSummary><gtr:fund><gtr:end>2010-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>794215</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Enzon Pharmaceuticals, Inc.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Evaluation of circulating tumour cells in a Phase I study of an antisense oligonucleotide to the androgen receptor</gtr:description><gtr:id>C0F50F94-0F7C-4544-BBE7-6B84E7AFB84F</gtr:id><gtr:impact>A clinical trial will be commencing in early 2010 and is just being submitted to the MHRA and REC</gtr:impact><gtr:outcomeId>UMWQY3L2J87-1</gtr:outcomeId><gtr:partnerContribution>Development of new methods to evaluate circulating tumour cell protein expression</gtr:partnerContribution><gtr:piContribution>We have written a clinical trial protocol for this novel antisense therapeutic to AR and developed biomarkers to assess its therapeutic effects</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>International and national research meetings</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CF3BC171-D7CB-4D84-9CF4-9B740BE37B3D</gtr:id><gtr:impact>Many thousand researchers listened to our work sparking much discussion and enthusiasm for this work

Our work has led to many (&amp;gt;200) prostate cancer trials utilizing CTC as clinical trial endpoints</gtr:impact><gtr:outcomeId>riCWDFDqHym</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>5204881</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>London Movember Prostate Cancer Centre, Ref. CEO13-2-002</gtr:description><gtr:end>2019-07-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:fundingRef>CEO13-2-002</gtr:fundingRef><gtr:id>018A70CB-ECBA-4439-ADFA-AB47A2C9150F</gtr:id><gtr:outcomeId>56cd90bb26e290.53679127</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3745484</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Re-AKT Study</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>AstraZeneca</gtr:fundingOrg><gtr:fundingRef>D3610C00013</gtr:fundingRef><gtr:id>126A8CC5-E168-4315-9C11-BE452548E9DE</gtr:id><gtr:outcomeId>56cdb45a9573b5.17311923</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Evaluating castration resistance in prostate cancer/Prostate Cancer Charity</gtr:description><gtr:end>2012-06-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:id>EE949BDA-3190-46F1-8E19-A8DD38849C9A</gtr:id><gtr:outcomeId>XAfDyEb9pt30</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>CTC frozen in cartridges</gtr:description><gtr:id>D01A8E52-60FB-4CBD-86BA-FDF2C9A254B2</gtr:id><gtr:impact>Analyses is ongoing but this work has led to the prostate cancer research community considering inter-patient heterogeneity in prostate cancer drug development</gtr:impact><gtr:outcomeId>UFtJVdnRonn</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>CTC frozen and stored from several hundred patients on the abiraterone Phase 3 trial</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C72A5935-AB54-481D-BFEA-1966A44F4B9E</gtr:id><gtr:title>Analysis of DNA methylation in single circulating tumor cells.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28bbb14e37d7e56a768d6ac472a31e77"><gtr:id>28bbb14e37d7e56a768d6ac472a31e77</gtr:id><gtr:otherNames>Pixberg CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>58c170d445ed22.98643120</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58513378-DB8C-4BA4-BA4A-4586AB043318</gtr:id><gtr:title>New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c5ee83798ec61595b58e2bb52b33b97"><gtr:id>8c5ee83798ec61595b58e2bb52b33b97</gtr:id><gtr:otherNames>Attard G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>pm_14441_21_21372223</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6E81AD0-32D0-45F9-9AFA-9185BC67BE6C</gtr:id><gtr:title>Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/465500d95966eaf15b951db1d4e0ba72"><gtr:id>465500d95966eaf15b951db1d4e0ba72</gtr:id><gtr:otherNames>Scher HI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>56cda599914278.58141564</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>510331E8-4B8E-40FE-BB4D-CA486F554FA3</gtr:id><gtr:title>Utilizing circulating tumor cells: challenges and pitfalls.</gtr:title><gtr:parentPublicationTitle>Current opinion in genetics &amp; development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c5ee83798ec61595b58e2bb52b33b97"><gtr:id>8c5ee83798ec61595b58e2bb52b33b97</gtr:id><gtr:otherNames>Attard G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0959-437X</gtr:issn><gtr:outcomeId>XGPspKUCYV1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D33C0DFF-6AEA-4F86-A575-11003FA0DACB</gtr:id><gtr:title>First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/06792f82025d4e6c72a5559c19c5833f"><gtr:id>06792f82025d4e6c72a5559c19c5833f</gtr:id><gtr:otherNames>Brunetto AT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>pm_540e148e1487a4ecf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3D541D6-A044-415A-9569-54F3671E7D07</gtr:id><gtr:title>Circulating biomarkers of neuroendocrine prostate cancer: an unmet challenge.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eff3bc998c0d06e4814c8f3e5332d9fa"><gtr:id>eff3bc998c0d06e4814c8f3e5332d9fa</gtr:id><gtr:otherNames>Rescigno P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>58c171d9e97d79.59990283</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B569EE1A-EFF5-4747-9164-1BA4D96041F9</gtr:id><gtr:title>PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f11cffa66f41d89845c0be80318d4c22"><gtr:id>f11cffa66f41d89845c0be80318d4c22</gtr:id><gtr:otherNames>Punnoose EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>56cda28b8c0f74.17577685</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A2821FC-A326-4CAE-ABAE-DF6BF66AB065</gtr:id><gtr:title>A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>CPT: pharmacometrics &amp; systems pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66d78dd748d02b9b50298ec6957ad908"><gtr:id>66d78dd748d02b9b50298ec6957ad908</gtr:id><gtr:otherNames>Wilbaux M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2163-8306</gtr:issn><gtr:outcomeId>56cda45fed1dc7.81009800</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1CD44FF-E5BC-4977-9F46-7A3CED617D1C</gtr:id><gtr:title>All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e517cfff04ef653a47b9e88de3a6e95"><gtr:id>9e517cfff04ef653a47b9e88de3a6e95</gtr:id><gtr:otherNames>Coumans FA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>KHnmEB7RJuw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6EF41A3-E282-444E-BF71-B1F6A1D2FB1F</gtr:id><gtr:title>Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef820ca01cbee0ab22ab194ed2ceb22c"><gtr:id>ef820ca01cbee0ab22ab194ed2ceb22c</gtr:id><gtr:otherNames>Lorente D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>58c1722ca5ab66.50851011</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E83B48DA-447A-4F0C-B8A5-17185D76C260</gtr:id><gtr:title>Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ed4d8d10fe20acf976d0782bf483405"><gtr:id>6ed4d8d10fe20acf976d0782bf483405</gtr:id><gtr:otherNames>Danila DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>pTxSe1UcrmU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFDA4F0A-590F-4C78-B9DB-819B9297E4B3</gtr:id><gtr:title>CCR 20th Anniversary Commentary: Circulating Tumor Cells in Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f5080669ee18bc95a96122b07974f8d"><gtr:id>6f5080669ee18bc95a96122b07974f8d</gtr:id><gtr:otherNames>Mehra N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>56cda248985bc8.64155662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CF1DCF6-9E58-4B84-BBA0-84EB7BBA2A8D</gtr:id><gtr:title>Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/581320b0225326381320ebec94005c2c"><gtr:id>581320b0225326381320ebec94005c2c</gtr:id><gtr:otherNames>McDaniel AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>58c17309ca4c54.85338553</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A7EA510-F385-4204-A338-13A9BCA187F3</gtr:id><gtr:title>The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d745cbb2c5e374e00a136e97420fc64"><gtr:id>1d745cbb2c5e374e00a136e97420fc64</gtr:id><gtr:otherNames>Heller G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>58c172d2212d19.59396932</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93B3BBC5-D769-4CDB-BD70-EF606B177FC0</gtr:id><gtr:title>Prostate cancer: PSA as an intermediate end point in clinical trials.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c5ee83798ec61595b58e2bb52b33b97"><gtr:id>8c5ee83798ec61595b58e2bb52b33b97</gtr:id><gtr:otherNames>Attard G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1759-4812</gtr:issn><gtr:outcomeId>NN6N5A6ZzfW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED9A8465-70E8-4B90-8F00-0123EBC256C3</gtr:id><gtr:title>Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c5ee83798ec61595b58e2bb52b33b97"><gtr:id>8c5ee83798ec61595b58e2bb52b33b97</gtr:id><gtr:otherNames>Attard G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>doi_55f9849841d3dd60</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFBB0858-160F-47D1-BACA-46C20AA8372E</gtr:id><gtr:title>Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c5ee83798ec61595b58e2bb52b33b97"><gtr:id>8c5ee83798ec61595b58e2bb52b33b97</gtr:id><gtr:otherNames>Attard G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>B88268994B4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3B15B11-1032-4292-B452-BA8B482B92B4</gtr:id><gtr:title>Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb6185d79137a579b502858f48f0b280"><gtr:id>fb6185d79137a579b502858f48f0b280</gtr:id><gtr:otherNames>Reid AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>GMGq8Vspg9d</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601308</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>